Yamaha Motor: Consolidated Business Results Summary
8.8.2023 19:00:00 EEST | Business Wire | Press release
Yamaha Motor Co., Ltd. (Tokyo:7272) announces its consolidated business results for the first half of fiscal 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808613856/en/
Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire)
Net sales for the consolidated accounting period for the first six months of the fiscal year ending December 31, 2023 were 1,226.4 billion yen (an increase of 157.5 billion yen or 14.7% compared with the same period of the previous fiscal year) and operating income was 142.8 billion yen (an increase of 40.3 billion yen or 39.4%). Ordinary income was 144.8 billion yen (an increase of 29.4 billion yen or 25.4%) and net income attributable to owners of parent was 105.3 billion yen (an increase of 22.3 billion yen or 26.9%). This is also the first time net income has exceeded 100 billion yen in a second quarter period.
For the first half-year consolidated accounting period, the U.S. dollar traded at 135 yen (a depreciation of 12 yen from the same period of the previous fiscal year) and the euro at 146 yen (a depreciation of 12 yen).
Market conditions during the second quarter were affected by factors that include subsiding outdoor recreation demand and a protracted economic recovery in China, but demand for large outboard motors and motorcycles remained strong. Compared to last year when the Company faced supply chain disruptions, marked improvements were made with product supply volumes and this resulted in higher sales. For operating income, higher unit sales as well as more pronounced effects from passing on costs to offset soaring prices for raw materials generated higher profits. Together with the positives of a weaker yen, led the Company to post record highs for net sales and incomes for a second quarter consolidated accounting period.
Forecast of Consolidated Business Results (Compared with the previous fiscal year)
Net Sales: 2,500 billion yen
(an increase of 251.5 billion yen or 11.2%)
Operating Income: 250.0 billion yen
(an increase of 25.1 billion yen or 11.2%)
Ordinary Income: 250.0 billion yen
(an increase of 10.7 billion yen or 4.5%)
Net Income Attributable to Owners of Parent: 180.0 billion yen
(an increase of 5.6 billion yen or 3.2%)
*Trading rate during the fiscal year: the U.S. dollar at 135 yen, the euro at 145 yen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808613856/en/
Contact information
Ayuko Kobayashi
Corporate Communication Division
Global PR Team
Yamaha Motor Co., Ltd.
TEL: +81(0)538-32-1145
ymc_pr@yamaha-motor.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom